eligibility_summary
Assigned via SWOG LUNGMAP S1900J with NSCLC and MET amplification (FMI tissue NGS), measurable disease, brain imaging, stable asymptomatic CNS mets allowed. Progressed after ≥1 line, recovered from prior therapy, no prior MET TKIs, no recent therapy/radiation/surgery or planned concurrent therapy. Adequate labs/organ function, Zubrod 0–2. Controlled HIV/HBV/HCV/diabetes. Exclude other actionable drivers/serious comorbidities. Contraception, not pregnant, consent and specimens.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm Expanded Lung-MAP sub-study testing amivantamab (subcutaneous), a bispecific IgG1 monoclonal antibody targeting EGFR and MET, in MET-amplified stage IV/recurrent NSCLC. Mechanism: binds EGFR and MET extracellular domains to block ligand-mediated activation, inhibit downstream oncogenic signaling, and promote receptor internalization/degradation, its Fc region engages immune effector cells to mediate ADCC. Targets: MET-amplified NSCLC cells with EGFR/MET dependence, key pathways include MET/EGFR-driven MAPK, PI3K/AKT, and JAK/STAT. Secondary immune engagement involves NK cells/macrophages via Fc. Primary endpoint: ORR, with PFS, OS, DoR, safety, serial ctDNA collected.